rexresearch.com


Emphysema Alternative Therapies








http://www.emphysemafoundation.org/index.php/living-with-copd/97-therapeutic-toolbox-articles/174-can-natural-remedies-help-treat-copd

Can Natural Remedies Help Treat COPD?

There is no shortage of natural remedies on the market today to treat, heal and cure our many ailments—chronic obstructive pulmonary disease (COPD) included. However, people living with COPD and other lung-related illnesses should be cautious when using these supplements to treat or manage their condition. That is according to a recent article published by Everyday Health.

Unlike prescription drugs, natural remedies are not regulated by the U.S. Food and Drug Administration and have not undergone the extensive research and scrutiny that prescription drugs receive before entering the marketplace. Therefore, many doctors and researchers are still uncertain about the effectiveness of these supplements, as well as their side effects.

Following are several natural supplements that have been said to remedy symptoms associated with COPD, as well as comments from experts on their effectiveness—or lack thereof.

Bromelain: A supplement created from the enzymes found in a pineapple’s stem and juice, bromelain is said to reduce inflammation associated with COPD. However, according to the National Institutes of Health, scientific evidence to support this claim is lacking.

Coenzyme Q10: An antioxidant that is naturally produced by the body, coenzyme Q10 has been said to increase cell activity and ease inflammation in people with COPD. Researchers have found that people living with COPD have especially low levels of coenzyme Q10; however, studies have not proven that taking the supplement improves conditions.

L-Carnitine: Typically produced by the body, L-carnitineis used to burn fat and boost energy. In COPD patients, this supplement appears to help strengthen muscles and improve endurance when exercising. Further, research has proven that those people who take L-carnitine supplements do significantly better during walking exercise programs.

N-acetylcysteine: An antioxidant available as an over-the-counter dietary supplement, N-acetylcysteine has been researched for its role in breaking down the mucus that can clog the lungs of people living with COPD. To date, research has showed mixed results on the supplement’s effectiveness.

Antioxidant vitamins: With properties of antioxidants, vitamins A, C and E have been said toimprove the lung function in people with COPD. Studies have shown that people living with COPD have low levels of these antioxidant-rich vitamins, and this deficiency can result in decreased pulmonary function. Further, studies have proven that COPD patients whose diets are rich in fruits and vegetables—a good source of vitamins A, C and E—saw improved lung function.

Note that natural remedies cannot serve as the sole source of COPD treatment. Consult with your physician before adding these supplements to your diet to ensure they do not interfere with current treatment methods.



http://www.dailymail.co.uk/health/article-204532/Vitamin-cure-emphysema.html

Vitamin 'cure' for emphysema

A vitamin found in eggs and milk could hold the key to curing the potentially fatal lung disease emphysema, new research has revealed.

British scientists have found that retinoic acid, a derivative of vitamin A, can reverse damage caused to the lungs by the previously incurable disease.

Tests on mice have found that damaged lungs have been repaired to normal by the compound, which is already used to treat chronic acne.

Trials are now being carried out to see if it could have similar success if used on humans.

Emphysema is one of the most common respiratory diseases in Britain and causes progressive damage to the lungs, which can eventually kill. There is currently no cure.

Early symptoms include breathlessness but sufferers can be left gasping for breath and reliant on oxygen.

It usually affects older people and is generally the result of long-term damage to the lungs caused by smoking or exposure to other harmful substances.

Professor Malcolm Maden, of the Medical Research Centre for Developmental Neurobiology at King's College, London, said his team's research held out "great hope" for the development of a treatment for emphysema in humans.

He said the retinoic acid compound worked on tissue cells in the lungs, causing them to regenerate.

Emphysema begins with the destruction of tiny air sacs (alveoli), which creates permanent "holes" in the walls of the lungs.

As the air sacs are destroyed the lungs are able to transfer less and less oxygen to the bloodstream.

Prof Maden said that during the tests on mice his compound made the alveoli grow back again until they returned to normal levels.

He said: "We saw quite dramatic results. It is potentially hopeful for emphysema sufferers, and for premature babies who often suffer from loss of alveoli because of treatments given to stimulate lung growth."

Clinical trials have begun in America to see if the treatment could be used on humans.

A spokeswoman from the British Lung Foundation gave the research a cautious welcome.

She said: "The BLF welcomes any interesting developments in research which may offer new options to patients with COPD (an umbrella term for chronic bronchitis and emphysema), a severely debilitating condition.

"However, the BLF would like to examine this research to understand fully whether this might be a viable option in the future.

"Currently, COPD is the fifth biggest killer worldwide and is the only major cause of death increasing in the UK."

The research was based on a chemical compound of retinoic acid taken from Vitamin A, and not from a dietary intake of the substance.


US2006063258
FACTOR
Inventor: MADEN MALCOLM / CORCORAN JONATHAN

US2004266715
Retinoic acid receptor beta-2, its agonists, and gene therapy vectors for the treatment of neurological disorders
Inventor:WONG LIANG FONG / MAZARAKIS NICHOLAS

US2007213290
Neurite regeneration
Inventor: KINGSMAN ALAN / MADEN MALCOLM

WO0175135
RETINOIC ACID RECEPTOR BETA-2, ITS ANTAGONISTS, AND GENE THERAPY VECTORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
Inventor: KINGSMAN ALAN JOHN / MADEN MALCOLM



http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085872/
Br J Pharmacol. 2011 May; 163(1): 106–115.
doi:  10.1111/j.1476-5381.2011.01246.x
PMCID: PMC3085872

Is a regenerative approach viable for the treatment of COPD?

Matthew Hind and Malcolm Maden

Abstract

Degenerative lung diseases such as chronic obstructive pulmonary disease (COPD) are common with huge worldwide morbidity. Anti-inflammatory drug development strategies have proved disappointing and current treatment is aimed at symptomatic relief. Only lung transplantation with all its attendant difficulties offers hope of cure and the outlook for affected patients is bleak. Lung regeneration therapies aim to reverse the structural and functional deficits in COPD either by delivery of exogenous lung cells to replace lost tissue, delivery of exogenous stem cells to induce a local paracrine effect probably through an anti-inflammatory action or by the administration of small molecules to stimulate the endogenous regenerative ability of lung cells. In animal models of emphysema and disrupted alveolar development each of these strategies has shown some success but there are potential tumour-inducing dangers with a cellular approach. Small molecules such as all-trans retinoic acid have been successful in animal models although the mechanism is not completely understood. There are currently two Pharma-sponsored trials in progress concerning patients with COPD, one of a specific retinoic acid receptor gamma agonist and another using mesenchymal stem cells.



http://www.sciencedirect.com/science/article/pii/S174504540700041X?np=y
doi:10.1016/j.rmedu.2007.02.012
Respiratory Medicine: COPD Update, Volume 3, Issue 2, June 2007, Pages 71

Can treatment with retinoids induce alveolar regeneration in people with smoking-related emphysema

Abstract

Background

Retinoids promote alveolar septation in the developing lung and stimulate alveolar repair in some animal models of emphysema.

Methods

One hundred forty-eight subjects with moderate-to-severe COPD and a primary component of emphysema, defined by diffusing capacity of the lung for carbon monoxide (Dlco) [37.1±12.0% of predicted] and CT density mask (38.5±12.8% of voxels <−910 Hounsfield units) [mean±SD] were enrolled into a randomized, double-blind, feasibility study at five university hospitals. Participants received all-trans retinoic acid (ATRA) at either a low dose (LD) [1 mg/kg/d] or high dose (HD) [2 mg/kg/d], 13-cis retinoic acid (13-cRA) [1 mg/kg/d], or placebo for 6 months followed by a 3-month crossover period.

Results

No treatment was associated with an overall improvement in pulmonary function, CT density mask score, or health-related quality of life (QOL) at the end of 6 months. However, time-dependent changes in Dlco (initial decrease with delayed recovery) and St. George's Respiratory Questionnaire (delayed improvement) were observed in the HD-ATRA cohort and correlated with plasma drug levels. In addition, 5 of 25 participants in the HD-ATRA group had delayed improvements in their CT scores that also related to ATRA levels. Retinoid-related side effects were common but generally mild.

Conclusions

No definitive clinical benefits related to the administration of retinoids were observed in this feasibility study. However, time- and dose-dependent changes in Dlco, CT density mask score, and health-related QOL were observed in subjects treated with ATRA, suggesting the possibility of exposure-related biological activity that warrants further investigation.



https://www.researchgate.net/publication/277365642_Retinoic_acid_fails_to_reverse_emphysema_in_adult_mouse_models
Thorax (Impact Factor: 8.29). 03/2004; 59(3):224-230.
DOI: 10.1136/thx.2003.010785

Retinoic acid fails to reverse emphysema in adult mouse models

Masaki Fujita

ABSTRACT

Background: Previous work has shown that all-trans-retinoic acid reverses elastase induced emphysema in rats.  

Retinoic acid fails to reverse emphysema in adult mouse models (PDF Download Available).



http://respiratory.publishingtechnology.com/content/article/10.1165/rcmb.2007-0252OC

American Journal of Respiratory Cell and Molecular Biology, Volume 38, Issue 2, pages 185 –191

Retinoic Acid–Induced Alveolar Regeneration : Critical Differences in Strain Sensitivity

Siân V. Stinchcombe, Malcolm Maden

In emphysema, the lung cannot spontaneously regenerate lost alveolar tissue. Treatment with retinoic acid (RA) in rodent models of emphysema induces alveolar regeneration. However, some animal studies have failed to show regeneration when using different species and strains. We have previously shown that dexamethasone (Dex) treatment of newborn TO outbred strain mice permanently disrupts alveolar development. Later RA treatment restores alveolar architecture to normal. To determine whether this model of alveolar regeneration is strain specific, our protocol was repeated with two new outbred mouse strains. ICR and NIHS mice received Dex from Postnatal Days 4 to P15 (P4– P15). From P46 to P57, mice received RA (2 mg/kg) or vehicle. An additional ICR group received 5× RA (10 mg/kg) from P46 to P57. Control groups received vehicle at both treatment points. All mice were killed at P90 and lung morphology analyzed. Dex-treated ICR and NIHS mice showed increased mean alveolar chord length (Lm) and reduced alveolar surface area (SA) and SA/lung volume (SA/LV) compared with controls. RA-treated NIHS mice showed return of Lm, SA, and SA/LV toward control values, indicating alveolar regeneration. ICR RA group mice did not regenerate, but 5× RA mice showed Lm, SA, and SA/LV values consistent with alveolar regeneration. In conclusion, the Dex-treated mouse model of emphysema is robust and repeatable in different strains. RA-induced alveolar regeneration is not a strain-specific phenomenon. RA dose threshold for inducing alveolar regeneration is higher in ICR mice, suggesting a difference in retinoid pharmacokinetics between strains. These results provide a possible explanation for previous failed studies of RA-induced alveolar regeneration.



http://www.uth.tmc.edu/apstracts/2001/lung/December/304l.html
APStracts 8:0304L, 2001.

Temporal/spatial expression of retinoid binding proteins and RAR isoforms in the postnatal lung.

Hind, Matthew, Jonathan Corcoran, and Malcolm Maden.
MRC Centre for Developmental Neurobiology, King's College London, London SE1 9RT, United Kingdom

Endogenous retinoids have been implicated in alveologenesis in both the rat and the mouse, and exogenous retinoic acid (RA) can reverse or partially reverse experimental emphysema in adult rat and mouse models by an unknown mechanism. In this study, we examine the cellular and molecular biology of retinoid signaling during alveologenesis in the mouse. We describe the temporal and spatial expression of the retinoid binding proteins CRBP-I, CRBP-II, and CRABP-I using RT-PCR and immunohistochemistry. We identify the retinoic acid receptor isoforms RAR-a1, RAR-ß2, RAR-ß4, and RAR-?2 and describe their temporal and spatial expression using RT-PCR and in situ hybridization. We demonstrate that both retinoid binding proteins and RAR isoforms are temporally regulated and found within the alveolar septal regions during alveologenesis. These data support a role of dynamic endogenous RA signaling during alveolar formation.



Patents

WO0228810
NEW RETINOIDS FOR THE TREATMENT OF EMPHYSEMA
The current invention provides novel retinoid compounds and methods for their synthesis, the use of such compounds for the preparation of medicaments for treating or preventing emphysema, cancer and dermatological disorders, methods for such deseases and pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders.

US6300350
TREATMENT OF EMPHYSEMA USING RAR SELECTIVE RETINOID ANTAGONISTS
This invention provides the use of RAR gamma selective agonists for the manufacture of a medicament containing one or more such agonists for the treatment of emphysema and other diseases associated with alveolar damage.In another aspect ,this invention provides the use of RAR agonists ,preferably a RAR gamma selective agonists for the manufacture of medicaments for promoting tropoelastin gene expression and alveolar matrix repair.

US2005113447
RETINOIDS FOR THE TREATMENT OF EMPHYSEMA.
This invention relates to new RAR selective retinoid agonists of formula (I) wherein the symbols are as defined in the specification to their pharmaceutically acceptable salts, individual isomers or to a racemic or non racemic mixture; to pharmaceutical compositions containing them, and to methods for their use as therapeutic agents.

US5998486
Treatment of emphysema with retinoic acid or other retinoids by inducing formation of gas-exchange units (alveoli)
This invention relates to the use of retinoic acid, its esters and analogues thereof, for treatment of emphysema. The method comprises administration of a composition containing an effective amount of a retinoic acid, or an ester or an analoge thereof, to induce alveolar formation

US6794416
Methods, compositions and modes of delivery for the treatment of emphysema using 13-cis-retinoic acid
The current invention is directed to methods of treating or preventing emphysema, pharmaceutical compositions suitable for the treatment or prevention of emphysema and methods for delivering formulations into the lung of a mammal suffering from emphysema. More generally, the invention encompasses the use of 13-cis-retinoic acid to treat or prevent certain chronic obstructive airway disorders, particularly chronic obstructive pulmonary disease including chronic bronchitis, emphysema and asthma in mammals, especially humans that smoke or smoked cigarettes. In another aspect, the present invention encompasses the use of pharmaceutical compositions of 13-cis-retinoic acid to treat emphysema.; Moreover, the current invention encompasses the use of electrohydrodynamic aerosol devices, aerosol devices and nebulizers to deliver formulations of 13-cis-retinoic acid into the lung of a mammal suffering from emphysema. The invention also encompasses the systemic use as well as the local use of 13-cis-retinoic acid. In a another aspect the current invention encompasses a pharmaceutical composition for preventing emphysema in a human at risk of emphysema through administration of a amount of 13-cis-retinoic acid, or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof in a pharmaceutically acceptable carrier, that is sufficient to prevent emphysema.

US2002035152
Use of inhaled retinoids in the treatment of lung diseases
Administration of retinoids by inhalation is used to overcome the chronic toxicity problems presented by systemic administration and to make retinoid therapy available as an option for the treatment of fibrotic lung disease, emphysema, and the prevention and treatment of epithelial cancers of the respiratory tract, especially those that are associated with tobacco use. Retinoids are administered by inhalation to the respiratory tract of the individual as an air-borne composition with a metered dose aerosol-producing inhaler, in which the retinoid is dissolved in a combination of a pharmaceutically acceptable chlorofluorocarbon propellant and an alkylamine solubilizing agent.

CN104800548
Traditional Chinese medicine composition for treating emphysema
The invention discloses traditional Chinese medicine composition for treating emphysema and belongs to the technical field of medicines for treating emphysema. The traditional Chinese medicine composition comprises raw materials in parts by weight as follows: 20-40 parts of pseudostellaria heterophylla, 5-15 parts of radix ophiopogonis, 5-15 parts of schisandra chinensis, 5-15 parts of honey-fried herba ephedrae, 10-30 parts of honey-fried cortex mori, 10-20 parts of semen ginkgo, 5-15 parts of honey-fried common coltsfoot flower, 5-15 parts of honey-fried aster root, 5-15 parts of perilla fruits, 5-15 parts of almonds, 5-15 parts of radix glycyrrhizae preparata, 5-15 parts of brassica alba boiss, 5-15 parts of semen raphani, 5-15 parts of pericarpium citri reticulatae, 5-15 parts of trichosanthes kirilowii maxim, 10-20 parts of cynanchum paniculatum, 10-20 parts of earthworms, 5-15 parts of polyporus umbellatus, 5-15 parts of ginger-processed pinellia, 20-40 parts of hedyotis diffusa and 1-5 parts of asarum. The efficacy of the traditional Chinese medicines is complementary; the traditional Chinese medicine composition has the effects of cough and asthma relief, qi depressing, phlegm reduction, wind and cold dispelling, qi replenishment, body fluid production, body resistance strengthening and pathogenic factor elimination, has remarkable and reliable treatment effect, takes effect quickly, has no toxic or side effect and is mild in property and low in cost.

CN104644936
Formula of traditional Chinese medicine for treating emphysema
A formula of a traditional Chinese medicine for treating emphysema is characterized in that the formula comprises Radix Codonopsis, Poria cocos, Rhizoma Atractylodis Macrocephalae, Rhizoma Pinelliae, honey-fried licorice root and dried orange peel; a preparation method of the traditional Chinese medicine comprises the following steps: weighing above medicinal materials according to weight proportions, mixing the medicinal materials, putting the obtained mixture in a medicinal pot, adding 3 large bowls of water, immersing for 3h, boiling with strong fire, slowly decocting with slow fire for about 30-40min to obtain one bowl of a soup, and filtering the soup; and an administration method of the traditional Chinese medicine is characterized in that the filtered soup is divided into two equal portions, the two equal portions are administrated warm every morning and evening, horizontal rest is carried out for 30min after the administration, one dose of the traditional Chinese medicine is administrated every day, and 9 doses compose a treatment course. The traditional Chinese medicine solves the problem of easy generation of side effects in present emphysema treatment, and is adapted to be clinically used in the emphysema treatment.

CN104491632
Application of traditional Chinese medicine composition in preparing medicine for treating bronchitis with emphysema
The invention belongs to the field of medicines, and in particular relates to an application of a traditional Chinese medicine composition in preparing a medicine for treating bronchitis with emphysema. The traditional Chinese medicine composition for treating bronchitis with emphysema comprises the following components: 14-16 parts of fritillaria praewalskii, 4-7 parts of astragalus membranaceus, 9-12 parts of clove, 9-12 parts of lily, 9-12 parts of achyranthes bidentata, 18-22 parts of rhizoma anemarrhenae, 14-16 parts of glossy privet fruit, 12-14 parts of eclipta prostrate, 4-6 parts of eucommia ulmoides, 4-6 parts of radix bupleuri, 8-12 parts of cassia twig, 10-14 parts of cenchrus echinatus, 6-10 parts of angelica sinensis, 8-10 parts of ginkgo leaves, 10-12 parts of wolfberry, 6-8 parts of radix ophiopogonis and 8-12 parts of liquorice. The traditional Chinese medicine composition has a very good treatment effect in treating bronchitis with emphysema, and has a remarkable clinical popularization value.

CN104474324
Traditional Chinese medicine composition for treating pulmonary emphysema
The invention discloses a traditional Chinese medicine composition for treating pulmonary emphysema, belonging to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials: divaricate saposhnikovia roots, platycodon grandiflorum, caulis bambusae in taeniam, wolfberries, trichosanthes Kirilowii maxim, almonds, cortex mori radicis, roots of common peony, peach kernels, poria cocosm pinellia ternate, pericarpium citri reticulatae, semen raphani, fructus aurantii, scutellaria baicalensis, immature bitter oranges, fructus forsythia, radix pseudostellariae, dandelion, salviae miltiorrhizae, cinnamon and agilawood. After mixing the medicines, the efficacies have a synergistic effect, so that the traditional Chinese medicine composition has the functions of warming yang and tonifying spleen, purging the lung of pathogenic fire and inducing diuresis, tonifying qi and yin and eliminating phlegm and freeing channels, can be used for treating both symptoms and root causes in the treatment course of pulmonary emphysema, can be mainly used for treating root causes while eliminating pathogenic factors, is free of any side effects to a human body, and has no adverse effect on the health of the patient.

CN104399003
Traditional Chinese medicine for treating emphysema
The invention discloses a traditional Chinese medicine for treating emphysema, belonging to the technical field of traditional Chinese medicines. The traditional Chinese medicine for treating emphysema is prepared from the following raw materials: radix ophiopogonis, magnolia officinalis, semen brassicae, dried tangerine or orange peel, fritillaria thun-bergli, calamus, curcuma aromatic, rhizoma alismatis, cassia twig, rhizoma atractylodis, atractylodes macrocephala, rhizoma anemarrhenae, sonchus olearleu, peony tree bark, astragalus membranaceus, codonopsis pilosula, adenophora stricta, peach kernels, houttuynia cordata, leonurus, schisandra chinensis and angelica sinensis. After the components are combined together, the traditional Chinese medicine has a synergistic effect, has the functions of nourishing liver and relieving dizziness, clearing away heat and toxic materials, smoothening the lung and relieving asthma as well as eliminating phlegm and freeing channels, can improve the organ immunity, can improve the anti-disease capability of human bodies and is definite in curative effect, rapid to take the effect into play, short in treatment course, and the disease does not reoccur after being treated.

CN104398568
Traditional Chinese medicinal composition for treating emphysema
The invention discloses a traditional Chinese medicinal composition for treating emphysema. The traditional Chinese medicinal composition consists of the following traditional Chinese medicaments: 15 to 20 grams of humulus scandens, 15 to 20 grams of heterophylly falsestarwort roots, 15 to 20 grams of balanophyllia sp, 8 to 12 grams of atractylodes, 8 to 12 grams of wolfiporia extensa, 5 to 10 grams of semen perillae acutae, 5 to 10 grams of radish seeds, 5 to 10 grams of white mustard seeds and 3 to 5 grams of licorice. A taking method of the traditional Chinese medicinal composition comprises the following steps: adding water for decoction, and taking decoction once a day for treatment in courses. According to the traditional Chinese medicinal composition, each traditional Chinese medicament has own efficacy, and when the traditional Chinese medicaments are used together, each function of a body can be balanced and conditioned to effectively fulfill the aim of treating emphysema.

CN104306868
Medicine composition used for treating lung and kidney qi deficiency type chronic obstructive emphysema and preparation method thereof
The invention discloses a medicine composition used for treating lung and kidney qi deficiency type chronic obstructive emphysema and a preparation method thereof. Raw medicine materials of the medicine composition comprise, astragalus, convolvulate asiabell roots, amomum, Chinese yam, mica, cordyceps liangshanensis, walnut kernels, agilawood, fructus psoraleae, fructus schizandrae, ginkgo, semen ziziphi spinosae, nutgall, polygonum cynanchoides hemsl, caulis bambusae in taeniis, caudate sweetleaf flowers, artemisia vestita, herbs of little platanthera, cerealose, white fungi and jujubes. The medicine composition has the advantages that the medicine composition is mainly used for nourishing the kidney and lung and preventing asthma and assists in astringing the lung to stop cough and regulating qi-flowing for eliminating phlegm, treats the lung and kidney qi deficiency type chronic obstructive emphysema, and has the advantages of being quick in working, accurate in treatment effect, high in safety, free of toxic function and not prone to reappearing.

CN104224979
Traditional Chinese medicine cataplasm for treating emphysema by plastering on acupoints and preparation method thereof
The invention provides a traditional Chinese medicine cataplasm for treating emphysema by plastering on acupoints and a preparation method thereof. The medicine-containing plaster layer of the cataplasm comprises, by weight, 1-6 parts of medicine extract, 4-10 parts of framework material, 2-6 parts of adhesive, 10-18 parts of humectant, 2-7 parts of filler, 0.5-2 parts of cross-linking agent, 1-3 parts of transdermal enhancer, 0.5-1 parts of pH regulator and 2-6 parts of isopropyl myristate; the medicine extract is prepared by extracting the following raw materials: lindley eupatorium, flowers carthami, peach kernel, herba epimedii, fructus psoraleae, astragalus membranaceus and salvia miltiorrhiza; the preparation method of the traditional Chinese medicine cataplasm comprises the steps of separately preparing the medicine extract and a blank matrix at first, and then adding the transdermal enhancer and the medicine extract into the blank matrix, and then adding isopropyl myristate, uniformly stirring and then coating a backing material with the mixture, and covering with a cover lining layer, thus obtaining the cataplasm. The cataplasm provided by the invention is good in adhesion force, can be adhered to the skin without residues, has remarkable treatment effect on emphysema, and can release medicine in vitro in a percutaneous way for 24 hours.

CN104161988
Traditional Chinese medicine preparation for treating emphysema
The invention discloses a traditional Chinese medicine preparation for treating emphysema. The traditional Chinese medicine preparation is prepared from 10 parts of pilose asiabell root, 9 parts of radix astragali , 12 parts of bighead atractylodes rhizome, 9 parts of arisaema cum bile, 9 parts of bitter orange, 12 parts of adenophora root, 9 parts of radix polygonati officinalis and 9 parts of bulb of fritillary. The traditional Chinese medicine preparation for treating emphysema has effects of eliminating dampness and reducing phlegm, and rectifying qi and invigorating spleen and can fast produce treatment effects on emphysema.

CN104027667
Traditional Chinese medicinal composition used for treating trachitis and emphysema and preparation thereof
The invention discloses a traditional Chinese medicinal composition used for treating trachitis and emphysema and a preparation method thereof. The traditional Chinese medicinal composition used for treating the trachitis and emphysema is prepared from the following raw materials in parts by weight: lily, coastal glehnia root, coix seed, epimedium, dogwood, Chinese angelica, almond, poria cocos, radix ophiopogonis, asparagus cochinchinensis, sea horse, tree peony bark, solanum cathayanum, gecko, snake gourd fruit shell, dried tangerine or orange peel, bitter orange, human placenta and liquorice. The invention provides a traditional Chinese medicinal composition which is nonirritant, has no toxic and side effect, is high in safety, can effect a radical cure, does not cause recurrence and can effectively treat the trachitis and emphysema and a preparation obtained by adopting the traditional Chinese medicine, and the obtained preparation has the advantages of short treatment cycle, good effect, quick effect and no recurrence. The traditional Chinese medicinal composition and the preparation thereof have high cure rate and effective rate when being used for treating the trachitis and emphysema, cure rate can be 93.8%, and effective rate can be 100%.

CN104013888
Traditional Chinese medicine composition for treating phlegm-heat lung-stagnation type obstructive emphysema and preparation method thereof
The invention discloses a traditional Chinese medicine composition for treating phlegm-heat lung-stagnation type obstructive emphysema and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw material medicines: thunberg fritillary bulb, caulis bambusae in taeniam, tabasheer, Platycodon grandiflorum, fructus perillae, the tuber of stemona, birthwort, flos farfarae, the root bark of white mulberry, Japanese Ardisia Herb, folium rhododendri daurici, Momordica grosvenori, rhizoma anemarrhenae, dayflower, Scutellaria baicalensis, Meadowrue Root and Rhizome, common andrographis Herb, Houttuynia cordata, lily, asparagus fern, Changium smyrnioides and rhizoma polygonati. The traditional Chinese medicine composition has the effects of clearing away the lung-heat and dissipating heat and calming the adverse-rising energy and relieving asthma and is mainly used for treating chronic phlegm-heat lung-stagnation symptoms of obstructive emphysema. By utilizing the theory of traditional Chinese medicine, the traditional Chinese medicine composition has the effects of regulating the disease resistance of the whole body, improving lung and bronchus tissue blood metabolism, enhancing the gas exchange efficiency, emphasizing on treatment based on syndrome differentiation in a targeted therapy manner, improving the diaphragm breath degree, promoting phlegm elimination, improving the respiratory muscle functions, keeping unobstructed airway and resisting infection.

CN104013886
Traditional Chinese medicine for treating pulmonary emphysema
The invention discloses a traditional Chinese medicine for treating pulmonary emphysema. The traditional Chinese medicine is prepared from the following raw material medicines in parts by weight: 30 parts of almond, 30 parts of common hogfennel root, 30 parts of fructus forsythiae, 25 parts of platycodon grandiflorum, 25 parts of rheum officinale, 25 parts of bulbus fritillariae cirrhosae, 20 parts of aster, 20 parts of motherwort, 20 parts of Mangnolia officinalis, 20 parts of the root bark of white mulberry, 20 parts of rhizoma atractylodis, 15 parts of Semen Trichosanthis, 15 parts of birthwort, 15 parts of the tuber of stemona, 15 parts of radix angelicae and 15 parts of asarum. According to the oral liquid, the preparation can rapidly relieve symptoms such as cough and asthmatic suffocating and expiratory dyspnea caused by pulmonary emphysema, realizes special treatment through a special medicine and is obvious in curative effect.

CN103989945
Traditional Chinese medicine decoction for treating emphysema
The invention discloses a traditional Chinese medicine decoction for treating emphysema. The decoction is composed of the following raw materials in parts by weight: 13 to 15 parts of rhizoma atractylodis, 15 to 20 parts of loquat leaf, 4 to 6 parts of ephedra stem, 5 to 7 parts of mahonia fortunei leaf, 3 to 5 parts of common andrographis herb, 2 to 4 parts of prunella vulgaris, 5 to 7 parts of cactus, 3 to 5 parts of balloonflower root, 2 to 4 parts of fructus liquidambaris, 4 to 6 parts of processed frankincense, 2 to 4 parts of cicada slough, 5 to 7 parts of pepperweed seed, 10 to 12 parts of dwarf lilyturf tuber, 3 to 5 parts of poria cocos, 2 to 4 parts of epimedium, 5 to 10 parts of Chinese magnoliavine, 3 to 5 parts of citron leaf, 2 to 3 parts of anredera cordifolia, 3 to 4 parts of wedelia chinensis, 1 to 3 parts of radix seu spiranthis lanceae, 1 to 2 parts of ophioglossum, 1 to 2 parts of potentilla limprichtii, 2 to 4 parts of oriental stephania root, and 2 to 3 parts of drymaria diandra. The traditional Chinese medicine decoction has the functions of dispelling cold, diffusing the lung, clearing qi, resolving stasis, nourishing yin, reducing internal heat, moistening the lung, resolving phlegm, relieving chest and abdominal distention, and dissipating binds, and has the advantages of good and rapid curative effect on emphysema treatment and no side or toxic effect.

CN103977168
Traditional Chinese medicine preparation for treating pulmonary emphysema
The invention discloses a traditional Chinese medicine preparation for treating pulmonary emphysema, and is characterized in that the traditional Chinese medicine preparation is prepared from the following traditional Chinese medicine raw materials by weight: 5-15 parts of prepared aconite lateral root, 5-20 parts of cortex mori, 5-20 parts of perillaseed, 5-20 parts of semen lepidii, 5-20 parts of cassia twig, 10-30 parts of polyporus umbellatus, 10-30 parts of poria, 5-20 parts of white atractylodes rhizome, 5-20 parts of herba lycopi, 5-20 parts of rhizoma alismatis, 5-20 parts of radix paeoniae rubra, and 20-40 parts of motherwort. Effects of strengthening body resistance and eliminating evil, clearing heat and detoxifying, helping yang qi and relieving exterior syndrome, ventilating lung and resolving phlegm are taken as principal things, effects of moistening and tonifying lung, relieving cough and eliminating phlegm are adopted for legislation, the pure natural Chinese herbal medicines are selected, and according to a traditional Chinese medicine theory formula and through strict screening and respective processing, the traditional Chinese medicine preparation having the advantages of significant effect, exact drug efficacy, relatively quick efficacy achieving, and small toxic and side effect on treatment of pulmonary emphysema is prepared through combination of a modern advanced technology preparing method.

CN103751513
Chinese medicinal composition for treating emphysema
The invention discloses a Chinese medicinal composition for treating emphysema. The Chinese medicinal composition is made of the following raw materials by weight part: 15-20 of almond, 10-15 of stiff silkworm, 10-15 of Fritillaria cirrhosa, 5-10 of cape jasmine, 15-20 of scutellaria, 10-15 of inula flowers, 5-10 of Tussilago farfara, 10-15 of ophiopogon japonicas, 5-10 of Cortex Mori, 8-12 of acorus calamus roots, 14-18 of Peucedanum praeruptorum, 16-22 of cassia twigs, 15-20 of stropanthus divericatus, 10-15 of walnut kernels, 12-16 of mango stones, 15-20 of Pseudostellaria heterophylla, 10-15 of bighead atractylodes rhizome, 5-10 of Poria, 10-15 of Herb of Chinese Chlamydoboea, 5-10 of bighead atractylodes rhizome, 10-15 of fructus perillae, 5-10 of ephedra, 10-15 of Belamcanda chinensis, and 10-15 of Chinese yam. The combined use of the various drugs provided by the invention has the efficacy of nourishing yin and invigorating lung, reinforcing qi and nourishing blood, promoting blood circulation to remove blood stasis, descending Qi and reducing phlegm, as well as relieving cough and asthma. The Chinese medicinal composition has the advantages of significant effect, exact efficacy, fast effect, and short treatment course, and has no toxic or side effect, is low in cost, and is safe and economical.

CN103705893
Traditional Chinese medicine composition for treating exogenous cold inner fluid emphysema
The invention discloses a traditional Chinese medicine composition for treating exogenous cold inner fluid emphysema. According to the exogenous cold inner fluid emphysema, pathological changes begin from the lung, then the spleen and kidney are affected, in later period, the heart is affected. Exogenous evil is easy to invade from the mouth, nose and skin, firstly invades and stays in the lung, so that the air comes in and goes out abnormally so as to cause rapid respiration, cough and expectoration. The traditional Chinese medicine composition is prepared from traditional Chinese medicines such as raw vine, craibiodendron leaf, fortunella leaf, herba chloranthi serrati, ginger, leucas zeylanica, ficus stenophylla, japanese polygala, herb of mother-of-thyme and root of desmos chinensis which can warm lung for dispelling cold and relieve exterior syndrome and remove fluid, and is decocted into decoction. Clinical tests show that total effective rate reaches 98.6%, the curative effect is remarkable, after treatment, the patient has no abnormal conditions in aspects such as blood, urine, stool routine, liver and kidney, has no irritability, and has no abnormal phenomena according to electrocardiogram observation.

CN103705742
Traditional Chinese medicine composite for treating lung-kidney qi deficiency type emphysema
The invention discloses a traditional Chinese medicine composite for treating lung-kidney qi deficiency type emphysema. The emphysema belongs to the fields of gasp syndrome, lung-distension, phlegm and retained fluid and the like; if a person is ill for a long time, the person is deficient in both lung and kidney and can not master and regulate qi so as not to horizontally lay by breathing in a propped way, and the person exhales more than inhalation, is low in voice and fright due to the deficiency of qi and can not be continuous in breath. The Chinese medicine treatment is favorable for tonifying the lung and nourishing the kidneys, depressing qi and relieving asthma as well as eliminating phlegm and stopping cough. According to the invention, a decoction is prepared by selecting traditional Chinese medicines, namely discolor ludisia herbs, walnut kernels, rhizoma drynariae, semen oroxyli, trichosanthes peel, thorny elaeagnus leaves, marsdenia tenacissima, pink reineckea herbs, Japanese metaplexis pericarp and sessile didissandra herb. Through a clinical test, the traditional Chinese medicine composite disclosed by the invention achieves the total effective rate of 98.3%, has no toxic side effect and is worthy of being clinically popularized and applied.

CN103705741
Traditional Chinese medicine preparation for treating sputum hot yu lung certificate type pulmonary emphysema
The invention discloses a traditional Chinese medicine preparation for treating sputum hot yu lung certificate type pulmonary emphysema. Pulmonary emphysema belongs to category of gasp syndrome, lung-distension and phlegm and retained fluid in traditional Chinese medicine, and the pathogenesis of sputum hot yu lung certificate type pulmonary emphysema is pent phlegm evil which is transformed into heat. The traditional Chinese medicine preparation disclosed by the invention selects traditional Chinese medicines narrow-leaved lindernia, paraphlonia, gnaphalium, herb of laminated sanicle, folium mori, Japanese glorybower flowers, nandina roots, parnassia wightiana wall, codonopsis convolvulacea, cymbidium pendulum and herb of little platanthera which have the functions of eliminating phlegm by cooling and freeing lung and relieving asthma and are decocted by water to form a decoction. Through clinical tests, the total efficiency reaches 98.3%. After treatment of patients, neither abnormalities in routine blood, urine and stool tests, hepatic and renal functions caused by taking the traditional Chinese medicine nor hypersensitivity exist. No abnormal phenomena are found in electrocardiogram observation.

CN103611061
Traditional Chinese medicinal composition for treating pulmonary emphysema
The invention discloses a traditional Chinese medicinal composition for treating pulmonary emphysema. The traditional Chinese medicinal composition comprises, 5-8 parts of Herba Houttuyniae, 3-5 parts of Japanese Raspberry Herb, 1-3 parts of Radix Pseudostellariae, 2-4 parts of Pepperweed Seed, 5-7 parts of Flos Inulae, 2-5 parts of Nomame Semaherb, 1-3 parts of Radix Astragali, 4-6 parts of Common Coltsfoot Flower, 2-4 parts of Luffa Vegetable Sponge, 4-6 parts of radish seed, 3-5 parts of Glabrous Greenbrier Rhizome, 1-3 parts of Erodium stephanianum Willd, 2-4 parts of Rhizoma Curcumae, 5-7 parts of Human Placenta, 2-4 parts of Herb of Klein cinquefoil, 1-3 parts of Prinsepia utilis Royle, 2-4 parts of Japanese Climbing Fern Spore, 8-10 parts of Chinese waxgourd pulp, 1-3 parts of Finelydivided Phtheirospermum, 1-2 parts of Zornia gibbosa and 1-3 parts of common nandina fruit. The traditional Chinese medicinal composition has body resistance strengthening, qi tonifying, blood nourishing, blood circulation invigorating, stasis removing, yin nourishing, lung nourishing, cold dispelling, lung diffusing, qi clearing and phlegm reducing effects, and has the advantages of good pulmonary emphysema treatment effect, fast effectiveness and no toxic side effects.

KR20130107533
PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE COMPRISING EXTRACT OF PHYLLOSTACHYS NIGRA MUNRO VAR. HENOSIS STAPF AS AN ACTIVE INGREDIENT
PURPOSE: A pharmaceutical composition for preventing and treating chronic obstructive pulmonary diseases is provided to offer medicine or health food for preventing and treating chronic obstructive pulmonary diseases by containing the extract of Phyllostachys nigra Munro var. henosis Stapf for reducing histiocytes in bronchoalveloar lavage fluid and neutophils as an active ingredient. CONSTITUTION: A pharmaceutical composition for preventing and treating chronic obstructive pulmonary diseases contains the extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient. The chronic pulmonary diseases are chronic bronchitis and pulmonary emphysema. A pharmaceutical composition for health food to prevent and treat chronic obstructive pulmonary diseases contains the extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient. A pharmaceutical composition for preventing and treating pulmonary diseases contains the extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient. [Reference numerals] (AA) Total inflammatory cell in pulmonary washing solution (*10^6); (BB) Bambusae caulis in Taenian

KR20130107532
PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE COMPRISING EXTRACT OF RHUS JAVANICA LINNE AS AN ACTIVE INGREDIENT
PURPOSE: A pharmaceutical composition for preventing and treating chronic obstructive pulmonary disease (COPD) is provided to reduce the number of macrophages, eosinophils, neutrophils, and lymphocytes in bronchoalveloar lavage fluid (BALF) using a Rhus javanica Linne extract, thereby being used as an active ingredient of pharmaceutical products and health foods for preventing and treating COPD. CONSTITUTION: A pharmaceutical composition for preventing and treating COPD contains a Rhus javanica Linne extract as an active ingredient. COPD includes chronic bronchitis or pulmonary emphysema. A composition for health foods for preventing and treating COPD contains the extract as an active ingredient. A pharmaceutical composition for preventing and treating lung diseases contains the extract as an active ingredient. [Reference numerals] (AA) Total inflammatory cell in waste washing solution (*10^6); (BB) Gallnut

KR20130107531
PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE COMPRISING EXTRACT OF LILIUM LANCIFOLIUM THUNBERG AS AN ACTIVE INGREDIENT
PURPOSE: A pharmaceutical composition for preventing and treating chronic obstructive pulmonary disease (COPD) is provided to reduce the number of macrophages, eosinophils, neutrophils, and lymphocytes in bronchoalveloar lavage fluid (BALF) using a Lilium lancifolium Thunberg extract, thereby being used as an active ingredient of pharmaceutical products and health foods for preventing and treating COPD. CONSTITUTION: A pharmaceutical composition for preventing and treating COPD contains a Lilium lancifolium Thunberg extract as an active ingredient. COPD includes chronic bronchitis or pulmonary emphysema. A composition for health foods for preventing and treating COPD contains the extract as an active ingredient. A pharmaceutical composition for preventing and treating lung diseases contains the extract as an active ingredient. [Reference numerals] (AA) Total inflammatory cell in waste washing solution (*10^6); (BB) Lily

CN103251791
Medicament for treating bronchitis complicated with emphysema
The invention discloses a medicament for treating bronchitis complicated with emphysema. The medicament is prepared from the following raw Chinese medicinal materials in parts by weight: 20g of honeysuckle, 12g of orange peel, 10g of rhizoma pinelliae preparata, 12g of cortex lycii radicis, 12g of perillaseed, 10g of semen brassicae, 10g of tendril-leaved fritillary bulb, 20g of cordate houttuynia, 10g of roasted flos farfarae, 12g of roasted aster, 12g of fructus aurantii, 10g of toasted almond, 12g of platycodon grandiflorum, 15g of bryozoatum, 10g of cynanchum glaucescens, 10g of roasted loquat leaf and 10g of liquorice. The medicament is prepared by carrying out multiple times of clinic composition compatibility on all the Chinese chemical materials; after being taken, the medicament has the capability of treating both symptoms and root causes starting from the overall human body and has the efficacies of relieving cough, moistening lung, freeing lung, relieving asthma, clearing away heat and toxic materials, moistening lung, descending qi, reducing phlegm, stopping cough, warming lung, eliminating phlegm, benefiting qi, removing stasis, activating meridians to stop pain and the like; hundreds of clinical trial cases prove that the medicament has a remarkable treatment effect in terms of treatment of the bronchitis and has high curative rate.

CN103142857
Chinese medicinal granules for treating bronchitis combined emphysema and preparation method thereof
The invention discloses Chinese medicinal granules for treating bronchitis combined emphysema. The Chinese medicinal granules mainly consist of honeysuckle, weeping forsythiae capsule, dahurian angelica roots, red peony roots, szechuan lovage rhizome, cocklebur fruits, divaricate saposhnikovia roots, dandelion, largetrifoliolious bugbane rhizome, licorice root, astragalus mongholicus, manchurian wildginger, common bletilla pseudobulb, mary rhododendron leaf and twig, alums, stiff silkworm, cassia twig, dangshen, nutgall and brown rat dung, has functions of reducing phlegm, relieving a cough and relieving chest tightness, relieves each discomfort symptoms caused by the bronchitis combined emphysema and has an obvious treatment function on the bronchitis combined emphysema.

CN103007020
Emphysema treatment drug and preparation method thereof
The invention discloses an emphysema treatment drug and a preparation method thereof. The emphysema treatment drug is characterized in that the emphysema treatment drug is prepared from natural pure traditional Chinese medicines of 20 to 30g of American ginseng, 20 to 30g of dark plum and 20 to 30g of fritillaria cirrhosa. The preparation method comprises blending the natural pure traditional Chinese medicines and rock sugar and immersing the mixture in rice vinegar. The emphysema treatment drug has effects of tonifying qi, moistening lung, producing astringency, generating body fluid and relieving a cough.

CN102335329
Medicine for treating emphysema, and preparation method thereof    
The invention belongs to the technical field of Chinese medicines, and particularly relates to a medicine for treating emphysema and a preparation method thereof. The prior art has the defects of long treatment course, side effect and low cure rate. The invention aims to provide the medicine for treating emphysema and the preparation method; the medicine for treating emphysema comprises the following raw materials in part by mass: 4 to 6 parts of rehmannia glutinosa, 5 to 8 parts of cinnamon, 3 to 7 parts of eucommia, 2 to 5 parts of himalayan teasel root, 1 to 4 parts of liquorice, 4 to 7 parts of Chinese yam, 4 to 8 parts of walnut meat, 10 to 16 parts of honey, 3 to 5 parts of dwarf lilyturf tuber, 4 to 6 parts of trichosanthes kirilowii maxim, 1 to 4 parts of fructus cormi, 2 to 6 parts of codonopsis pilosula, 4 to 8 parts of astragalus and 3 to 5 parts of root of bidentate achyranthes. Compared with the prior art, the medicine has the advantages of scientific formula, high cure rate, no side effect, low cost and short treatment course.

CN102139078
Traditional Chinese medicine for treating pulmonary diseases
The invention discloses a traditional Chinese medicine for treating pulmonary diseases, relating to traditional Chinese medicines. Each dose of the product comprises the following raw medicines in proportions by weight: 25g of stemona, 25g of lily, 20g of hyacinth bletilla, 20g of bulbus fritilariae, 15g of ephedra, 20g of loquat flower, 15g of Japanese edelweiss flower, 20g of ficus microcarpa and 500g of honey. The preparation method of the traditional Chinese medicine comprises the following steps of: preparing the raw medicines according to the formula, wherein the ephedra is roasted in advance; drying, crushing and mixing the stemona, lily, hyacinth bletilla, bulbus fritilariae, ephedra, loquat flower, Japanese edelweiss flower and ficus microcarpa, and then adding the honey; stirring uniformly to prepare pills according to conventional processes; and qualifying to obtain products. The clinical application result of the traditional Chinese medicine for treating pulmonary diseases shows that the traditional Chinese medicine has an obvious treatment effect and can relieve a cough and treat asthma after being taken for 2 hours; generally, patients with bronchitis can be cured by taking 3-5 doses of the products, and patients with emphysema can be cured by continuously taking 5-7 doses of the products; and patients with phthisis need to take the medicine for a longer time, and the cure rate is more than 75%.

CN102078499
Chinese patent medicine for treating emphysema
The invention relates to a Chinese patent medicine for treating emphysema, comprising the following components: 60 parts of fritillary bulb, 80 parts of cortex mori, 10 parts of caulis hocquariae manshuriensis, 20 parts of schisandra, 35 parts of paniculate swallowwort root, 40 parts of radix sileris and 10 parts of bulbus fritillariae cirrhosae. The Chinese patent medicine has simple prescription, high curative rate and short treatment period without relapse and is clinically proved to have 85% of effective rate and 75% of curative rate.

CN101979015
Chinese medicinal preparation for treating respiratory diseases of chronic tracheitis, emphysema and pulmonary heart disease
The invention discloses a Chinese medicinal preparation for treating respiratory diseases of chronic tracheitis, emphysema and pulmonary heart disease, which is prepared from inula, glossy ganoderma, peach seed, almond, malaytea scurfpea fruit, herba epimedii, south dodder seed, medlar, astragalus, honey-fried michaelmas daisy and the like through the conventional preparation processes of traditional Chinese medicines. The Chinese medicinal preparation has the advantages of obvious curative effect, small toxic and side effect, quick clinical transference cure, no toxic or side effect, short treatment period, no relapse after healing and low treatment cost; simultaneously, the Chinese medicinal preparation can relieve the economical burden of patients, and the patients can stop taking the Chinese medicinal preparation and are difficult to relapse after healing.

CN101843874
Chinese medicament for treating emphysema
The invention relates to a Chinese medicinal composition, in particular to a Chinese medicament for treating emphysema. The Chinese medicament is characterized in that: the Chinese medicament is prepared from the following raw materials in par by weight: 3 to 5 parts of glutinous rice root hair, 4 to 6 parts of hedgehog hide, 2 to 4 parts of sharpleaf galangal fruit, 2 to 4 parts of himalayan teasel root, 3 to 5 parts of tree-of-heaven ailanthus bark, 2 to 4 parts of apocynum venetum, 3 to 5 parts of diverse wormwood herb, 4 to 6 parts of China rose, 3 to 5 parts of ginseng, 3 to 5 parts of dwarf lilyturf tuber, 4 to 6 parts of largehead atractylodes rhizome, 3 to 5 parts of peach seed, 3 to 5 parts of dry ant, 2 to 4 parts of pepperweed seed, 2 to 4 parts of Chinese magnoliavine fruit and 3 to 5 parts of rehmannia glutinosa.; The Chinese medicinal composition has the advantages of good curative effect, short treatment course, low cost, moderate taste, no bitter taste, moderation, easy use, no toxic or side effects, simple preparation method, and simple and readily available raw materials.

WO9964029
PLANT EXTRACT
Plant extracts obtained from Bactris plants have been found to provide effective therapeutic treatment for diabetes, aquired immunodeficiency syndrome, influenza, common cold symptoms, pulmonary emphysema, bronchitis, poliomyelitis, macular degeneration, cancer, gingivitis, dermatitis, hair loss, hepatitis, genital herpes, papilloma, and asthma. Therapy can be administered as an aqueous extract of the plant or portions of the plant, or as a powder prepared from the plant or portions of the plant.





Your Support Maintains this Service --

BUY

The Rex Research Civilization Kit

... It's Your Best Bet & Investment in Sustainable Humanity on Earth ...
Ensure & Enhance Your Survival & Genome Transmission ...
Everything @ rexresearch.com on a Data DVD !

ORDER PAGE

Rex Research, POB 19250, Jean, NV 89019 USA